Dr Loren Flynn is a postdoctoral research scientist working with Professor Anthony Akkari in the Motor Neurone Disease Genetics and Therapeutics Research group based at the Perron Institute and at CMMIT, Murdoch University. She joined the newly established MND group in 2017 after completing her PhD at UWA and the Perron Institute, under the supervision of Prof Steve Wilton and Prof Sue Fletcher.
Loren’s research focuses on identifying antisense oligonucleotide therapeutics for neurodegenerative diseases, including MND and Parkinson’s disease, targeting key mechanisms of disease pathology. Loren is currently the Director for Therapeutic Development with US biotech company Black Swan Pharmaceuticals, driving the pre-clinical development of their antisense therapy portfolio.

View Publications    Email